Request a Quote |
Login
Home > Company News > Trading Update

Trading Update

January 5th 2010

Cyprotex PLC ("Cyprotex" or "the Company" or "the Group")

Cyprotex (LSE:CRX), the drug discovery technology and information company, notes yesterday's fall in the share price and is unaware of any reason for this share price movement. The Company re-iterates that its current trading is in line with market expectations following its trading update of 20 November 2009.

The Company expects to release a trading update towards the end of January 2010, in respect of calendar year ended 31 December 2009.

For further information:

Cyprotex PLC

Dr Anthony Baxter, Chief Executive Officer

John Dootson, Chief Financial Officer

Tel: +44 (0) 1625 505 100

ir@cyprotex.com

www.cyprotex.com

Noble & Company

John Llewellyn-Lloyd

Tel: +44 (0) 20 7763 2200

john.llewellyn-lloyd@noblegp.com

www.noblegp.com

Financial Dynamics

Ben Brewerton / Ben Atwell / John Dineen

Tel: +44 (0) 20 7831 3113

cyprotex@fd.com

www.fd.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000

 

Email:
enquiries@cyprotex.com

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Close